Urinary N-methylhistamine as an indicator of bone marrow involvement in mastocytosis

Clinical and Experimental Dermatology

Volumn 27, Issue 6, 2002, Pages 502-506

  Oranje, A P ^a   Riezebos, P ^a   Van Toorenenbergen, A W ^a   Mulder, P G H ^a   Heide, R ^a   Tank, B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATINE; N METHYLHISTAMINE;

ARTICLE; BONE MARROW BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; HUMAN; MAST CELL; MASTOCYTOSIS; PRIORITY JOURNAL; URINALYSIS;

BIOLOGICAL MARKERS; BIOPSY; BONE MARROW; HUMANS; MAST CELLS; MASTOCYTOSIS; METHYLHISTAMINES; ROC CURVE; SENSITIVITY AND SPECIFICITY; SKIN;

EID: 0036411736     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2002.01072.x     Document Type: Article

References (31)

1. Golkar L, Bernhard JD. Mastocytosis [see comments]. Lancet 1997; 349: 1379-85.
2. Valent P. Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr 1996; 108: 385-97.
3. Metcalfe DD. Classification and diagnosis of mastocytosis: Current status. J Invest Dermatol 1991; 96: 2S-4S.
4. Tebbe B, Stavropoulos PG, Krasagakis K et al. Cutaneous mastocytosis in adults. Evaluation of 14 patients with respect to systemic disease manifestations. Dermatology 1998; 197: 101-8.
5. Kettelhut BV, Metcalfe DD. Pediatric mastocytosis. J Invest Dermatol 1991; 96: 15S-18S.
6. Horny HP, Parwaresch MR, Lennert K. Clinical picture and prognosis of generalized mastocytosis. Klin Wochenschr 1983; 61: 785-93.
7. Topar G, Staudacher C, Geisen F et al. Urticaria pigmentosa: A clinical, hematopathologic, and serologic study of 30 adults. Am J Clin Pathol 1998; 109: 279-85.
8. Czarnetzki BM, Kolde G, Schoemann A et al. Bone marrow findings in adult patients with urticaria pigmentosa. J Am Acad Dermatol 1988; 18: 45-51.
9. Travis WD, Li CY, Bergstralh EJ et al. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 1988; 67: 345-68.
10. Horny HP, Parwaresch MR, Lennert K. Bone marrow findings in systemic mastocytosis. Hum Pathol 1985; 16: 808-14.
11. Grardel B, Hardouin P. Mastocytosis and bone manifestations. Results of the survey of the bone and phosphorus-calcium metabolism section of the French Society of Rheumatology. Rev Rhum Mal Osteoartic 1992; 59: 57-63.
12. Grieser T, Minne HW. Systemic mastocytosis and skeletal lesions [letter; comment]. Lancet 1997; 350: 1103-4.
13. Lawrence JB, Friedman BS, Travis WD et al. Hematologic manifestations of systemic mast cell disease: A prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 1991; 91: 612-24.
14. Rafii M, Firooznia H, Golimbu C et al. Pathologic fracture in systemic mastocytosis. Radiographic spectrum and review of the literature. Clin Orthop 1983; 180: 260-7.
15. Longley BJ Jr, Metcalfe DD, Tharp M et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999; 96: 1609-14.
16. Buttner C, Henz BM, Welker P et al. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: A possible explanation for divergent clinical behavior. J Invest Dermatol 1998; 111: 1227-31.
17. Worobec AS, Semere T, Nagata H et al. Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer 1998; 83: 2120-9.
18. Brunel V, Tadrist Z, Cailleres S et al. Interferon alpha and pamidronate: A useful combination in the treatment of osteoporosis and systemic mastocytosis [letter]. Presse Med 1998; 27: 64.
19. Johansson C, Roupe G, Lindstedt G et al. Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing 1996; 25: 1-7.
20. Marshall A, Kavanagh RT, Crisp AJ. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol 1997; 36: 393-6.
21. Granerus G, Wass U. Urinary excretion of histamine, methylhistamine (1-MeHi) and methylimidazoleacetic acid (MeImAA) in mastocytosis: Comparison of new HPLC methods with other present methods. Agents Actions 1984; 14: 341-5.
22. Martens-Lobenhoffer J, Neumann HJ. Determination of 1-methylhistamine and 1-methylimidazoleacetic acid in human urine as a tool for the diagnosis of mastocytosis. J Chromatogr B Biomed Sci Appl 1999; 721: 135-40.
23. Roupe G, Granerus G. Long-term follow-up of histamine turnover in mastocytosis. Int Arch Allergy Appl Immunol 1987; 82: 62-5.
24. Granerus G, Lonnqvist B, Roupe G. No relationship between histamine release measured as metabolite excretion in the urine, and serum levels of mast cell specific tryptase in mastocytosis. Agents Actions 1994; 41: C127-128.
25. Granerus G, Lonnqvist B, Nystrand J et al. Serum tryptase measured with B12 and G5 antibody-based immunoassays in mastocytosis patients and its relation to histamine turnover. Br J Dermatol 1998; 139: 858-61.
26. Van Gysel D, Oranje AP, Vermeiden I et al. Value of urinary N-methylhistamine measurements in childhood mastocytosis. J Am Acad Dermatol 1996; 35: 556-8.
27. Swets JA. Indices of discrimination on diagnostic accuracy: Their ROC's and implied models. Psychol Bull 1986; 99: 100-17.
28. Morrow JD, Guzzo C, Lazarus G et al. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2. J Invest Dermatol 1995; 104: 937-40.
29. Moreno F, Blanca M, Fernandez J et al. Determination of inflammatory markers in allergic reactions to drugs. Allergy Proc 1995; 16: 119-22.
30. Oosting E, Keyzer JJ. Measurement of urinary N taumethylhistamine excretion: Correlation of a newly developed radioimmunoassay (RIA) with gas chromatography mass spectrometry (GCMS). Agents Actions 1991; 33: 215-7.
31. El-Mansoury M, Boucher W, Sant GR et al. Increased urine histamine and methylhistamine in interstitial cystitis. J Urol 1994; 152: 350-3.